Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
An update on the association of natalizumab (TYSABRI) with Progressive Multifocal Leukoencephalopathy (PML) - Important Safety Information from Elan and Biogen Idec (Ireland) Limited as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
22/02/2010
Problem Or Issue:
Important Safety Information communication from Elan and Biogen Idec (Ireland) Limited.
Important Safety Information - Natalizumab (TYSABRI)
« Back
Date Printed: 05/05/2024